25/10/2004
ReGen Therapeutics Plc (‘ReGen’), a company developing a treatment for Alzheimer’s Disease, is pleased to announce that all of the conditions to the acquisition of the entire issued share capital of Guildford Clinical Pharmacology Unit Limited (the ‘Acquisition’) have now been satisfied and that the Acquisition was completed earlier today.
Admission of the 7,692,308 new ordinary shares of ReGen to trading on the AIM market of the London Stock Exchange, issued as consideration for the Acquisition also took place earlier today.
For further information, please contact:
Andrew Marshall
Marshall Robinson Roe
Tel No: 0207 960 6007